Similar articles

• Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation.

  Peggs KS, Hunter A, Chopra R, Parker A, Mahendra P, Milligan D, Craddock C, Pettengell R, Dogan A, Thomson KJ, Morris EC, Hale G, Waldmann H, Goldstone AH, Linch DC, Mackinnon S. Peggs KS, et al. Lancet. 2005 Jun 4-10;365(9475):1934-41. doi: 10.1016/S0140-6736(05)66659-7. Lancet. 2005. PMID: 15936420
• Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

  Sureda A, Robinson S, Canals C, Carella AM, Boogaerts MA, Caballero D, Hunter AE, Kanz L, Slavin S, Cornelissen JJ, Gramatzki M, Niederwieser D, Russell NH, Schmitz N. Sureda A, et al. J Clin Oncol. 2008 Jan 20;26(3):455-62. doi: 10.1200/JCO.2007.13.2415. Epub 2007 Dec 17. J Clin Oncol. 2008. PMID: 18086796
• Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusion.

  Todisco E, Castagna L, Sarina B, Mazza R, Anastasia A, Balzarotti M, Banna G, Tirelli U, Soligo D, Santoro A. Todisco E, et al. Eur J Haematol. 2007 Apr;78(4):322-9. doi: 10.1111/j.1600-0609.2007.00814.x. Epub 2007 Jan 23. Eur J Haematol. 2007. PMID: 17253967 Clinical Trial.
• Autologous and allogeneic stem cell transplantation in Hodgkin's lymphoma.

  Sureda A. Sureda A. Hematol Oncol Clin North Am. 2007 Oct;21(5):943-60. doi: 10.1016/j.hoc.2007.07.008. Hematol Oncol Clin North Am. 2007. PMID: 17908630 Review.
• Allogeneic transplantation of hematopoietic stem cells after nonmyeloablative conditioning for Hodgkin's disease: indications and results.

  Schmitz N, Sureda A, Robinson S. Schmitz N, et al. Semin Oncol. 2004 Feb;31(1):27-32. doi: 10.1053/j.seminoncol.2003.10.018. Semin Oncol. 2004. PMID: 14970934 Review.